The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRTX | +114.12% | -96.34% | -48.41% | -94% |
| S&P | +14.5% | +93.32% | +14.09% | +133% |
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
The FDA's latest move regarding one of this biopharma's investigational drugs all but slams the door shut on its future.
Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | 20.5% |
| Market Cap | $75.02M | 131.5% |
| Market Cap / Employee | $2.08M | 0.0% |
| Employees | 36 | 12.5% |
| Net Income | -$16.05M | 42.1% |
| EBITDA | -$9.86M | -12.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.83M | 113.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.38M | 21.6% |
| Short Term Debt | $0.11M | 19.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.91% | 8.6% |
| Return On Invested Capital | -65.98% | -18.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.54M | -31.5% |
| Operating Free Cash Flow | -$11.42M | -30.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.72 | 1.80 | 1.94 | 3.92 | 796.11% |
| Price to Tangible Book Value | -2.27 | -4.13 | -1.96 | -1.66 | -72.72% |
| Enterprise Value to EBITDA | -0.13 | -5.56 | -3.30 | -6.07 | -518.86% |
| Return on Equity | -83.2% | -98.6% | -130.9% | -167.0% | 110.44% |
| Total Debt | $15.45M | $14.81M | $15.75M | $17.49M | 21.60% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
